Sarah Worley

Ms. Sarah Worley

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in The Annals of Thoracic Surgery
Verified
Journal Article
Open access
SAShahnawaz Amdani
Shahnawaz Amdani
GBGerard Boyle
Gerard Boyle
ESElizabeth V. Saarel
Elizabeth V. Saarel
JGJustin Godown
Justin Godown
Wei LiuWei Liu
Wei Liu
TKTara Karamlou
Tara Karamlou
Although outcomes for pediatric cardiomyopathy (CMP) patients have improved, an understanding of outcomes by CMP phenotype is essential. This study assessed changes in waitlist and post-transplant survival in nondilated cardiomyopathy (DCM) patients over 2 decades, explored ventricular assist device (VAD) utilization in this cohort, and identified risk factors for waitlist and posttransplant mortality in the current era. Pediatric patients with a diagnosis of CMP listed for heart transplantation during three eras: Era 1: March 5, 1999 to December 31, 2004; Era 2: January 1, 2005 to December 15, 2011; and Era 3 (current era): December 16, 2011 to February 28, 2018 were included. Multivariable Cox proportional hazards regression was performed to assess waitlist and posttransplant survival. Compared with patients with DCM, those with hypertrophic and restrictive cardiomyopathy in the current era are less likely to be on VAD (23.4% vs 2.7% vs 4.5%); listed United Network for Organ Sharing Status 1A (75.6% vs 39.8% vs 34.8%), and more likely to have longer waitlist times (P < .01 for all). Only 3.3% hypertrophic and 2.4% restrictive cardiomyopathy patients had VAD implantation, although VAD use did not adversely impact waitlist survival in weighted non-DCM patients. Significant improvements have occurred in waitlist survival of hypertrophic and posttransplant survival of both types of non-DCM patients. Currently, waitlist and posttransplant survival is similar for all CMP phenotypes. VAD use is low in patients with non-DCM, although this did not increase waitlist mortality in adjusted analysis. Further studies in patients with non-DCM are needed to determine optimal timing and anatomic characteristics most likely to benefit from VAD implantation during the waitlist period.

1 April 2011 in Journal of Pediatric and Adolescent Gynecology
Verified
Journal Article
Closed access
LGLaura Gillespie
Laura Gillespie
CHCaitlin W. Hicks
Caitlin W. Hicks
MSMelissa Santana
Melissa Santana
SWSarah Worley
Sarah Worley
DBDavid A. Banas
David A. Banas
EREllen S. Rome
Ellen S. Rome

27 April 2022 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
AKAml S. Kelada
Aml S. Kelada
TFTimothy B. Foster
Timothy B. Foster
GGGregory C. Gagliano
Gregory C. Gagliano
SWSarah Worley
Sarah Worley
ATAnne Tang
Anne Tang
CFCharles Foster
Charles Foster
Objective: To assess central venous catheter (CVC) harm in pediatric oncology patients, we explored risks for central-line–associated bloodstream infections (CLABSIs) and central-line–associated non-CLABSI complications (CLANCs).Design: Retrospective cohort study.Setting: Midwestern US pediatric oncology program.Patients: The study cohort comprised 592 pediatric oncology patients seen between 2006 and 2016.Methods: CLABSIs were defined according to Centers for Disease Control and Prevention (CDC)/National Health Safety Network (NHSN) definitions. CLANCs were classified using a novel definition requiring CVC removal. Patient-level and central-line–level risks were calculated using a negative binomial model to adjust for correlations between total events and line numbers.Results: CVCs were inserted in 62% of patients, with 175,937 total catheter days. The inpatient CLABSI and CLANC rates were 5.8 and 8.5 times higher than outpatient rates. At the patient level, shared risks included acute myeloid leukemia (AML) and age <1 year at diagnosis. At the line level, shared risks included age 1 lumen. AML was a CLABSI-specific risk. CLANC-specific risks included non–brain-tumor diagnosis, younger age at diagnosis or central-line placement, and age 1 lumen and for CLANC age <1 year at placement.Conclusions: Among patients with CVCs, CLABSI and CLANC rates were similar, higher among inpatients than outpatients. For both CLABSIs and CLANCs, infants and patients with AML were at higher risk. In both univariate and multivariate models, lines with >1 lumen were associated with CLABSIs and placement during infancy with CLANCs.

14 July 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
NKNeelakanta Kanike
Neelakanta Kanike
KHKrupa Gowri Hospattankar
Krupa Gowri Hospattankar
ASAmit Sharma
Amit Sharma
SWSarah Worley
Sarah Worley
SGSharon Groh-Wargo
Sharon Groh-Wargo
Vitamin D is not only a vital element in bone health but is also a prohormone. Data regarding distribution of vitamin D status among preterm and term neonates in the United States are limited. There are no data on the effect of intrauterine drug exposure on vitamin D status. Our objective was to determine the distribution of vitamin D levels among preterm and term neonates and the effect of intrauterine illicit drug exposure. We did a retrospective chart review of neonates admitted from 2009 to 2016 to our neonatal intensive care unit with serum 25-hydroxycholecalciferol (25[OH]D) levels measured during the hospital stay. Of 1517 neonates, the median 25[OH]D level was 19 ng/mL with 31% deficient and 49% insufficient, even though 75% of mothers took prenatal vitamins. In pregnant women, 38% were vitamin-D-deficient and 44% were vitamin-D-insufficient. Four hundred seventy-one neonates had intrauterine drug exposure, with a median 25[OH]D level of 22.9 ng/mL versus 17.8 ng/mL in nonexposed neonates (p = 0.001). Despite maternal prenatal vitamin intake, neonates are at risk of vitamin D deficiency. Maternal illicit drug use was not related to lower 25[OH]D levels in neonates.

1 June 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
NKNeelakanta Kanike
Neelakanta Kanike
SGSharon Groh-Wargo
Sharon Groh-Wargo
MTMegan Thomas
Megan Thomas
ECEdward K. Chien
Edward K. Chien
MMMaroun Mhanna
Maroun Mhanna
PSPrem Shekhawat
Prem Shekhawat
Iodine is an essential component of thyroid hormones, which play a critical role in neurodevelopment. The iodine status of pregnant women and their newborns is not checked routinely. Extremely Low Gestational Age Newborns do not receive Iodine supplementation while on parenteral nutrition (PN). We measured urine iodine levels and thyroid function tests in 50 mother–infant dyads at birth, at 1 week, 1, 2, 3 months and near discharge. We correlated maternal and neonatal urine iodine levels with thyroid functions and measured iodine levels in milk and PN. In our study, 64% of mothers were iodine deficient at the time of delivery, their free T4 levels were 0.48 (0.41–0.54) ng/dL with normal thyroid-stimulating hormone (TSH). Iodine levels were thirty-fold higher in extremely low gestational age newborns (ELGAN) exposed to iodine comparing to full terms (p < 0.001), but this effect lasted <1 week. At 1 month of age, ELGAN on PN developed iodine deficiency (p = 0.017) and had high thyroglobulin levels of 187 (156–271) ng/mL. Iodine levels improved with enteral feeds by 2 months of age (p = 0.01). Iodine deficiency is prevalent among pregnant women and ELGAN; in particular, those on PN are at risk of hypothyroidism. Iodine supplementation during pregnancy and postnatally should be considered to avoid iodine deficiency.

1 April 2008 in Emerging Infectious Diseases
Verified
Journal Article
Open access
PDF file
SYStephanie Yee-Guardino
Stephanie Yee-Guardino
KGKate Gowans
Kate Gowans
BYBelinda Yen-Lieberman
Belinda Yen-Lieberman
PBPamela Berk
Pamela Berk
DKDebra Kohn
Debra Kohn
JGJohanna Goldfarb
Johanna Goldfarb
We conducted a cross-sectional study of β-herpesviruses in febrile pediatric oncology patients (n = 30), with a reference group of febrile pediatric solid-organ transplant recipients (n = 9). One (3.3%) of 30 cancer patients and 3 (33%) of 9 organ recipients were PCR positive for cytomegalovirus. Four (13%) of 30 cancer patients and 3 (33%) of 9 transplant recipients had human herpesvirus 6B (HHV-6B) DNAemia, which was more common within 6 months of initiation of immune suppression (4 of 16 vs. 0 of 14 cancer patients; p = 0.050). HHV-6A and HHV-7 were not detected. No other cause was identified in children with HHV-6B or cytomegalovirus DNAemia. One HHV-6B–positive cancer patient had febrile disease with concomitant hepatitis. Other HHV-6B–positive children had mild “viral” illnesses, as did a child with primary cytomegalovirus infection. Cytomegalovirus and HHV-6B should be included in the differential diagnosis of febrile disease in children with cancer.